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An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in
part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable
environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel
therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our
study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a
drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful
conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To
this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse
model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine,
metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral
phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and
antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive
symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype
after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term
potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when
administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach
than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective
interventions to increase the efficacy of the antidepressant drugs currently available.
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1. Introduction
Selective serotonin reuptake inhibitors (SSRIs) are the most
commonly prescribed drugs for the treatment of major
depressive disorder (MDD), which constitutes an enormous
medical, individual, societal, and economical challenge and
afflicts up to 10–15% of the population worldwide [1].
However, the efficacy of SSRIs is variable and incomplete:
60–70% of patients do not experience remission and 30–
40% do not show a significant response [2]. To explain such
incomplete efficacy, a novel hypothesis—named undirected
susceptibility to change—posits that the increase in serotonin
levels induced by SSRIs does not affect mood per se but
enhances brain plasticity and thus amplifies the influence of
the environment on the individual [3–6]. Therefore, SSRI
treatment has not a univocal effect, but in a favorable envi-
ronment, it would lead to a reduction of symptoms while in
a stressful environment, it has limited efficacy and may even
lead to a worse prognosis [7].
A number of evidence support a role for serotonin in
increasing brain plasticity and enhancing susceptibility to
the environment [3, 8, 9]. In addition, the undirected suscep-
tibility to change hypothesis has been recently demonstrated
at preclinical and clinical levels. In preclinical studies, it has
been shown that fluoxetine (FLX), one of the most com-
monly prescribed SSRIs, affects the molecular and behavioral
depression-like phenotype according to the quality of the
living environment: when administered in an enriched envi-
ronment, it led to an improvement while, when administered
in a stressful environment, FLX treatment led to a worsening
of depression-like endpoints such as an enhanced anhedonic
behavior and a reduced neurogenesis [5, 10]. At a clinical
level, it has been demonstrated that the commonly used SSRI
citalopram amplifies the influence of the living conditions
on mood, confirming that SSRI effects are affected by the
environment [11].
The SSRI action on brain plasticity and susceptibility to
the environment opens new perspectives on how to
improve the efficacy of these antidepressants by improving
the quality of the patients’ living environment. However,
often, it is not possible to act on the environment because
of constraints due to patient’s personal history and
unchangeable life circumstances. In these cases, the phar-
macological modulation of the factors underlying the link
between the living environment and SSRI action represents
a novel and desirable strategy to improve treatment out-
come in patients living in adverse conditions, very common
in depressed patients.
Metabolism is markedly affected by the quality of the
living environment. For instance, having an active physical
and social life profoundly modulates metabolic markers
[12, 13]. In turn, the metabolic profile affects vulnerability
to MDD and antidepressant efficacy. As an example, normal-
ization of metabolic markers has been associated to remis-
sion following antidepressant treatment, while no change
occurs in nonremitters [14]. Therefore, modification of
metabolism represents a potential approach to modulate
the interplay between the environment and SSRIs in order
to improve treatment outcome.
The aim of the present study was to assess whether the
pharmacological modulation of metabolism may improve
the limited efficacy of FLX when administered in a stressful
environment. To this purpose, we used metformin (MET),
a widely used drug to treat type II diabetes and other
metabolic syndromes [15]. It affects the metabolic profile at
both peripheral and central levels since it crosses the blood-
brain barrier [16, 17]. Though the underlying molecular
mechanisms of MET action are yet to be fully determined,
it has been reported in preclinical models that MET affects
brain plasticity, increasing long-term potentiation (LTP) in
the hippocampal CA1 region [18] and modulating neuro-
trophic factor levels, such as the brain-derived neurotrophic
factor (BDNF) [19].
Our prediction was that the combined FLX and MET
treatment is more effective than FLX alone in counteracting
a depression-like phenotype in a stressful environment.
According to our hypothesis, such enhanced efficacy is
ascribable to the combined action of the two drugs: FLX
increases brain plasticity, favoring a change in mood, while
MET, which affects the metabolic profile, drives the change
toward an improvement. To this aim, we measured BDNF
expression and LTP as molecular and cellular markers of
neural plasticity, in addition to liking- and wanting-type
anhedonia as endpoints of depression-like response.
2. Materials and Methods
2.1. Animals. C57BL/6 male mice 12–15 weeks old were used
and kept under a 12-hour light-dark cycle at 22–25°C. Mice
were purchased at Envigo Italia (Udine, Italy). All procedures
were carried out in accordance with the European law
(EEC Council Directive 2010/63/UE86/609 1987), Italian
legislation on animal experimentation (Decreto Legislativo
26/2014). In addition, animals were routinely examined for
signs of discomfort as indicated by the animal care and
use of the National Academy of Sciences of USA guidelines
(National Research Council 2003).
2.2. Housing Condition. For the entire duration of the
experiment, animals were housed in the IntelliCage system
(TSE Systems, NewBehavior AG, Zürich, Switzerland), which
is an apparatus for automatic monitoring of mouse behavior.
It consists of a large acrylic cage (20.5 cm high, 58 cm × 40 cm
at the top, and 55 cm × 37 5 cm at the base, Model 2000 Tec-
niplast, Buguggiate, VA, Italy) with 4 walls separating each
corner from the center so that they form 4 identical triangu-
lar conditioning chambers (15 × 15 × 21 cm). Animals have
access to the chamber by entering a front hole (chamber
entrance). Only one mouse at a time can enter the chamber.
Once entered, it is identified through a transponder antenna
system. The system is able to collect data about the number
and duration of visits and the number, duration, and side
(right or left) of nosepokes and licks. The floor of the cage
was covered with bedding and contains four sleeping shelters
in the center while on the top, a food rack is present filled
with standard mouse chow (food ad libitum). An addi-
tional cage (SocialBoxes) was used to expand the existing
IntelliCage to a multiarea system; thus, we increased the
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capacity of the system to test simultaneously more mice.
One week before being moved to the IntelliCage, each ani-
mal was injected with a subcutaneous transponder (T-IS
8010 FDX-B; Datamars SA, Switzerland). Mice have been
gradually habituated to the IntelliCage environment during
a 14-day period (habituation period).
2.3. Treatment. After the first two weeks of stressful condi-
tion, aimed at inducing a depression-like phenotype, mice
continued to be exposed to the unpredictable chronic mild
stress (see below) for 4 weeks receiving one of the following
treatments: VEH, FLX, MET, or FLX and MET together.
FLX (Fluoxetine HCl, Santa Cruz, USA) and MET
(Metformin, Sigma-Aldrich, St Louis, MO, USA) were dis-
solved in water and in saccharin solution and delivered ad
libitum in the drinking bottles for 4 weeks. Compared to
injection, this administration method allows avoiding the
stress due to the manipulation. The solutions were prepared
according to the mouse average weight and daily water
consumption in order to provide an average daily intake of
30mg/kg of FLX [20] and 200mg/kg of MET, respectively
[21, 22]. Bottles with FLX and with FLX and MET were
wrapped in tin foil to protect the substance from light.
Metformin, fluoxetine, and their combination were dissolved
in both water and saccharin solution to avoid that the saccha-
rin preference could affect the amount of drug received. The
average amount of fluoxetine or metformin administered did
not differ among the experimental groups receiving the same
compound. Though we did not perform a pharmacokinetic
analysis, to our knowledge, no interaction between fluoxetine
and metformin has been reported.
2.4. Environmental Conditions. All mice were exposed to the
stressful condition for two weeks to induce the depression-
like behavior. For the following 4 weeks, the subjects went
on being exposed to the stressful condition or were exposed
to the standard condition.
2.4.1. Stressful Condition. Mice were exposed to unpredict-
able chronic mild stress procedure to induce depression-
like behavior (Figure S1). To prevent habituation to stress,
mice were exposed each day to a different stressful
procedure, randomly chosen among the procedures
provided by the IntelliCage. The procedures were short
open door: the door to access water or saccharin solution
remains open for only 1.5 seconds; delay: the door opens
with a delay of 1, 1.5, 2, and 2.5 seconds after the first
nosepoke; open door 25%: the door opens only following
25% of nosepokes; and air puff: when the mouse performs a
visit, it has a 20% chance to receive an air puff (2 bar)
which lasts 1 sec or until the animal leaves the corner. In
the latter case, the doors remain closed. Once each one of
these procedures ended, in order to reopen the doors and
drink again, the animals had to leave the corner and start a
new visit. The duration of each stressful procedure was
randomly chosen: 12, 18, or 24 hrs. In addition, during the
stressful condition, no shelter or tissue paper was provided.
2.4.2. Standard Condition. Mice were socially housed in the
IntelliCages and exposed to Plexiglas shelters of different
colors and shapes (four red transparent Tecniplast plastic
nest boxes and four white opaque boxes) and to tissue paper.
New paper was provided every 5 days, and the plastic shelters
were cleaned every week (Figure S2(a)).
2.5. Behavioral Tests. Behavioral endpoints investigated are
liking- and wanting-type anhedonia. These were automati-
cally assessed by the IntelliCage avoiding any bias or stress
due to the experimenter.
2.5.1. Liking-Type Anhedonia: Saccharin Preference. To
assess liking-type anhedonia, we measured the saccharin
preference. Two bottles were present in each corner of
the IntelliCage, one containing tap water and the other
containing the 0.1% saccharin solution; both were freely
available 24/24 h. Water and saccharin solution were
substituted every day. The position of water and sac-
charin in each corner was counterbalanced across the
four corners. The saccharin preference was determined
as follows: saccharin solution consumed/saccharin solution
consumed + water consumed × 100. We measured the
baseline saccharin preference across a two-day period (i) at
the end of the habituation period, (ii) at the end of the first
two weeks of exposure to the stressful condition (aimed at
inducing the depression-like phenotype), (iii) 1 week after
the beginning of the treatment period, and (iv) at the end
of the treatment period. Mice were exposed to the saccharin
solution only (all bottles filled with saccharin solution) dur-
ing the first two days of the IntelliCage habituation period
in order to make them used to the saccharin flavor. In the
remaining 12 days, mice could choose between water and
saccharin solution.
2.5.2. Wanting-Type Anhedonia: Progressive Ratio Schedule.
To assess wanting-type anhedonia, i.e., the drive for obtain-
ing a reward, we used the progressive ratio reinforcement
schedule that utilizes a multiplicative increase in the number
of responses (nosepokes) required to dispense a unit of
reinforce (i.e. access to saccharin). In particular, water was
always accessible after one nosepoke while saccharin solution
was accessible only after a specific number of nosepokes that
increases progressively. After each series of 8 visits, the
number of nosepokes required to access saccharin increases
according to the following schedule: 1, 2, 3, 4, 5, 6, 7, 8, 10,
12, 16, 20, and 24. After reaching the 24 nosepoke level, mice
had free access to saccharin following one nosepoke. The
time for performing the nosepokes increased gradually
according to the number of nosepokes requested from one
to 24 sec. Mice were exposed to this test at the end of the
habituation period, immediately before the treatment period
and after both 1 and 4 weeks of treatment. To make the mice
aware of the progressive ratio testing, the three LEDs on the
top of each door were kept turned on throughout the test.
Each test session lasted two days.
2.6. RNA Extraction and RT-RTqPCR. Following 4 weeks of
treatment in the stressful condition, animals were sacrificed
by decapitation, the brains were removed, and the dorsal
and ventral parts of the hippocampus were dissected, rapidly
frozen, and then stored at −80°C for further molecular
3Neural Plasticity
analyses. The same animals tested for behavior were analyzed
for mRNA expression. Total RNA, from the ventral and
dorsal hippocampi, was prepared combining extraction with
TRI Reagent® and GenElute™ Mammalian Total RNA
Miniprep Kit and (Sigma Aldrich ®, Milan, Italy) as previ-
ously described [4]. Two μg of total RNA was reverse
transcribed using High-Capacity cDNA Reverse Transcrip-
tion Kit (Thermo Fisher Scientific, Waltham, MA USA) in
a final reaction volume of 20μL [23]. The cDNA was stored
at −20°C until real-time PCR that was performed in Roche
LightCycler® 480 (Roche Diagnostics GmbH, Roche Applied
Science, Mannheim, Germany) using Power SYBR Green
Mix (Life Technologies Corporation, Carlsbad, CA, USA).
The following forward and reverse sequences were used at
the final concentration of 150nM: for IGF1 F5′-TGCTCT
TCAGTTCGTGTG-3′ and R5′-ACATCTCCAGTCTCCT
CAG-3′; for IGF2 F5′-CGCTTCAGTTTGTCTGTTCG-3′
and R5′-GGAAGTACGGCCTGAGAGGTA-3′; for BDNF
F5′-CCATAAGGACGCGGACTTGTAC-3′ and R5′-AGAC
ATGTTTGCGGCATCCAGG-3′; for p11 (S100a10) F5′-
CTTCAAAATGCCATC CCAAA-3′ and R5′-TATTTTGT
CCACAGCCAGAGG-3′, for leptin F5′-AAGAAGATC
CCAGGGAGGA and R5′-TGATGAGGGTTTTGGTGTCA,
and for glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
F5′-TTCGCAAAACAAGTTCACCA-3′ and 5′-TCGTTG
TGGTTGTAAATGGAA-3′ as a house-keeping gene. Melt
curve analyses and agarose gel separations were performed
at the end of every RTqPCR to confirm formation of a single
PCR product. The Ct (cycle threshold) value was deter-
mined by the LightCycler® 480 Software (Roche Diagnostics
GmbH, Roche Applied Science, Mannheim, Germany),
and mRNA expression was calculated with the ΔΔCt
method with GAPDH as endogenous control as previously
described [24]. Relative expression of the genes of interest
was performed by using as calibrator (RQvalue = 1) expres-
sion levels in the ventral hippocampi of vehicle-treated
animals. All qPCR reactions based upon the same primer
set were run in the same amplification plate to compare
the levels of mRNA expression between the two parts of
the hippocampus.
2.7. Electrophysiology
2.7.1. Hippocampal Slice Preparation. In order to perform
electrophysiological experiments, acute hippocampal slices
were collected. At the end of the treatment period in the
stressful condition, animals were anesthetized by inhalation
of halothane (Sigma-Aldrich S.r.l., Milan, Italy) and decapi-
tated. The brain was rapidly removed from the skull and
immersed in ice-cold artificial cerebrospinal fluid (ACSF)
solution composed of the following (in mM): NaCl 125,
KCl 4, CaCl2 2.5, MgSO4 1.5, NaHPO4 1, NaHCO3 26,
and glucose 10. ACSF was continuously bubbled with 95%
O2 + 5% CO2 to maintain a pH close to 7.4.
Following removal, the brain was hemisected along the
longitudinal fissure to separate the two hemispheres. Brain
dissection was carried out according to the slicing plane
chosen and the structure to be investigated. Specifically, for
experiments on the ventral hippocampus, slices were cut
perpendicular to the longitudinal axis from the temporal pole
of the brain. For experiments on the dorsal hippocampus,
coronal slices were cut from the frontal pole. Dorsal and
ventral slices have been identified as the distance, in μm,
from the frontal and temporal pole, respectively (approxi-
mately from 400 to 1750μm). The brain tissues were blocked
on the stage of a vibrating microtome (Thermo Scientific,
USA), and 350μm-thick slices were cut in ice-cold ACSF.
The slices were then transferred to an incubation chamber
containing oxygenated ACSF, where they were allowed to
recover for 1 h at 30°C prior to electrophysiological record-
ing. After this period, the slices were transferred to the inter-
face slice-recording chamber (BSC1, Scientific System Design
Inc.) to perform experiments within 1–6 h after slice prepara-
tion. Dorsal and ventral slices were prepared from separate
hemispheres of the same brain and were obtained alternately
from the right or left hemisphere.
2.7.2. Extracellular Field Recordings. For field recordings,
individual slices were maintained at 30–32°C and superfused
with ACSF at 2mL/min by a peristaltic pump. A concentric
bipolar stimulating electrode (SNE 100 × 50mm long, Elek-
tronik Harvard Apparatus GmbH) was placed in the stratum
radiatum to stimulate Schaffer collateral fibers. Stimuli con-
sisted of 100μs constant current pulses of variable intensities,
applied at 0.05Hz. A glass micropipette (0.5–1MΩ) filled
with ACSF was placed in the CA1 hippocampal region, at
200–600μm from the stimulating electrode, in order to
measure orthodromically evoked field extracellular postsyn-
aptic potentials (fEPSP). Stimulus intensity was adjusted to
evoke fEPSP of amplitude about 50% of the maximal ampli-
tude with minimal contamination by a population spike.
Evoked responses were monitored online, and stable baseline
responses were recorded for at least 10min. Only the slices
that showed stable fEPSP amplitudes were included in the
experiments. LTP was induced by high-frequency stimula-
tion (HFS) (1 train of stimuli at 100Hz of 1 s duration),
repeated after 30min. To analyze the time course of the
fEPSP slope, the recorded fEPSP was routinely averaged over
1min (n = 3). The fEPSP slope changes following the LTP
induction protocol at 31 and 61min post tetanus were calcu-
lated with respect to those of the baseline (1minute before
induction). N/n refers to the number of slices on the total
number of mice analyzed.
The paired-pulse ratio (PPR) was measured from
responses to two synaptic stimuli at 50ms interstimulus
interval. PPR was calculated as the ratio between the fEPSP
amplitude evoked by the second stimulus (A2) and that by
the first (A1; A2/A1).
fEPSP were recorded and filtered (low pass at 1 kHz) with
an Axopatch 200A amplifier (Axon Instruments, CA) and
digitized at 10 kHz with an A/D converter (Digidata 1322A,
Axon Instruments). Data acquisition was stored on a com-
puter using pClamp 9 software (Axon Instruments) and ana-
lyzed offline with Clampfit 10 program (Axon Instruments).
2.8. Data and Statistical Analysis. All data were analyzed with
one-way ANOVA with the statistical software StatView II
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(Abacus Concepts, CA, USA), comparing VEH versus FLX-,
MET-, and FLX plus MET-treated mice. When a significant
main effect was found, selected pairwise comparisons were
made using Tukey’s post hoc analysis.
3. Results
3.1. FLX and MET Combination Is Effective in Alleviating
Depression-Like Behavior. As behavioral phenotypes of
depression, we assessed the liking- and wanting-type anhe-
donia, which have been previously shown to be susceptible
to stress and SSRI treatment [5, 10, 25].
The two weeks of chronic stress before treatment was
effective in inducing a depression-like profile. In particular,
the saccharin preference (liking-type anhedonia) dropped
from around 90 to 55 percent (F 1, 37 = 87 870, p < 0 0001,
Figure 1(a)) and the breakpoint level (wanting-type anhedo-
nia) was significantly reduced (F 1, 39 = 17 874, p < 0 0001,
Figure 1(b)). No difference in weight between treated and
control groups was found (data not shown), indicating that
the stress procedure did not differentially affect the experi-
mental groups. Following the induction of a depression-like
profile, mice receiving the combination of FLX and MET
showed an improvement of their behavioral phenotype when
compared to those of the other experimental groups. Spe-
cifically, following 1 week of treatment, liking-type anhedo-
nia was significantly affected by treatment (F 3, 34 = 6 126,
p = 0 0019); post hoc analysis revealed that FLX-MET mice
displayed an increased saccharin preference compared
to VEH, FLX, and MET mice (p < 0 05, p < 0 05, and
p < 0 001, respectively; Figure 1(a)). Wanting-type anhe-
donia was significantly affected by treatment as well
(F 3, 35 = 3 047, p = 0 0414). FLX-MET mice showed a
significant increase of the breakpoint level compared to
both FLX and MET mice (p < 0 05 and p < 0 05, respec-
tively; Figure 1(b)). At the end of the treatment, the pro-
longed exposure to stress (6 weeks) led to a marked
anhedonic profile in all groups, flattening the potential
differences in liking-type anhedonia. As for wanting-type
anhedonia, a significant main effect of treatment was found
(F 3, 35 = 4 329, p = 0 0107). In particular, FLX-MET mice
reached a higher breakpoint level compared to MET mice
(p < 0 001, Figure 1(b)).
All mice to be treated in the standard condition showed a
significant increase of the depression-like phenotype follow-
ing the two weeks of exposure to the stressful condition
(Figures S2(b) and (c)). In particular, both liking-type
anhedonia (F 1, 41 = 43 721, p < 0 0001) and wanting-type
anhedonia (F 1, 40 = 10 681, p = 0 0022) were significantly
reduced. Afterwards, when receiving VEH, FLX, MET, or
FLX-MET in a standard condition, they showed no
difference in depression-like behavior. In particular, all
experimental groups showed a full recovery, displaying no
anhedonic response, both at 1 and 4 weeks of treatment.
3.2. IGF2 mRNA Levels Are Increased in the Dorsal
Hippocampus of Mice Receiving the Combined Treatment.
To explore the molecular bases of treatment effect, we ana-
lyzed gene expression of selected targets reported to be
involved in MDD and metabolism. In particular, we focused
on IGF2 and IGF1, p11, BDNF, and leptin mRNA expression
in the dorsal and ventral hippocampus. These hippocampal
areas have been reported to be differently involved in MDD
















































































Figure 1: Effects of treatment with fluoxetine, metformin, or their combination on depression-like behavior. (a) Liking-type anhedonia.
Saccharin preference significantly decreased following exposure to stressful procedure. After the first week of treatment, FLX-MET mice
displayed an increased saccharin preference compared to both VEH, FLX, and MET mice. (b) Wanting-type anhedonia. The breakpoint
level was significantly reduced after the unpredictable chronic mild stress. Following the first week of treatment, FLX-MET mice showed a
significant increase of the breakpoint level compared to both FLX and MET mice. Treatments as indicated in the legend, n = 9 − 10 mice
per group. $$p < 0 0001 pre- vs poststress, ∗p < 0 05 and ∗∗p < 0 001 vs VEH, #p < 0 05 and ##p < 0 0001 vs FLX, and +p < 0 05 and
++p < 0 001 vs MET. Data are presented as mean + SEM.
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IGF2 analysis revealed a significant main effect of treat-
ment (F 3, 50 = 3 370, p = 0 0256) and a significant interac-
tion treatment × hippocampal region (F 3, 50 = 5 912,
p = 0 0015; Figure 2(a)). Post hoc analysis revealed that, overall,
mice receiving the combined treatment showed higher IGF2
expression compared to those of the VEH and FLX groups.
With regard to the dorsal hippocampus, they displayed higher
IGF2 levels compared to VEH (p < 0 05), MET (p < 0 05), and
FLX (p < 0 01). FLX-MET mice showed also significantly
higher IGF2 levels in the dorsal region compared to the ventral
region (p < 0 01). As for the other geneticmarkers investigated,
IGF1, BDNF, p11, and leptin, we found no effect of treatment
but a significant main effect of the hippocampal region
(Fs 1, 50 = 29 161, 96 221, 114 972, 126 865, ps < 0 001,
Figures 2(b)–2(e)). In particular, IGF1 and BDNF levels
were higher in the dorsal hippocampus, while p11 and
leptin were higher in the ventral hippocampus.
3.3. LTP in the Dorsal and Ventral Hippocampal Regions Is
Differentially Affected by Treatment. We explored plasticity
processes in the CA1 hippocampal region by recording LTP
evoked by two spaced (30minutes apart) Schaffer collateral
stimulations in both the dorsal and ventral hippocampus.
Interestingly, during the second stimulation, the main effect
of treatment emerged (F 3, 60 = 3 321, p = 0 026). In
addition, the main effect on the hippocampal area and tr
eatment × hippocampal region interaction were very close
to reach statistical significance (F 1, 60 = 3 473, p = 0 067
and F 3, 60 = 2 523, p = 0 066, respectively). Post hoc
analysis revealed that, in the dorsal hippocampus, FLX-
MET-treated mice show an increased LTP amplitude
(1 495 ± 0 065) compared to MET- (1 226 ± 0 061, p < 0 05)
and VEH- (1 260 ± 0 058, p < 0 05, Figure 3(a), left) but not
to FLX- (1.406±0.069) treatedmice. By contrast, in the ventral
region, the combined treatment showed a trend toward a
reduction of LTP amplitude compared to FLX and VEH
alone (1 387 ± 0 058 vs 1 525 ± 0 065 and 1 479 ± 0 061,
Figure 3(a), right) but was similar to MET alone
(1 323 ± 0 0759). Finally, in the VEH group, the magnitude
of LTP was higher in the ventral compared the dorsal
hippocampus (p = 0 012).
With regard to PPR, a main effect on the hippocampal
region was observed following treatment (F 1,139 = 157 357,
p < 0 001), being its value higher on the dorsal hippocampus
for all treatments (p < 0 001, Figure 3(b)). In the VEH
group, PPR was 1 402 ± 0 034 and 1 081 ± 0 041, in the dor-













































































































Figure 2: Effects of fluoxetine, metformin, or their combination on expression of genes involved in brain plasticity in the dorsal and ventral
hippocampi. (a) IGF2 is significantly increased by the combined treatment compared to VEH and FLX alone, suggesting that this growth
factor is involved in the antidepressant action of the FLX-MET treatment. Such effect concerned the dorsal hippocampus, where FLX-
MET treatment increased IGF2 expression compared to all the other groups. (b) IGF1, (c) p11, (d) BDNF, and (e) leptin expression was
not affected by treatment, but IGF1 and BDNF levels were overall higher in the dorsal hippocampus, while p11 and leptin were higher in
the ventral hippocampus. Treatments as indicated in the legend, n = 6 – 8 mice per group. £££p < 0 001, the main effect of the hippocampal
region; §p < 0 05 and §§p < 0 01 vs FLX-MET in the dorsal region. Data are presented as mean + SEM.
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4. Discussion
The present results show that the combination of FLX and
MET administered in the stressful condition ameliorates
the depression-like phenotype compared to FLX and VEH
alone after one week but not after four weeks of treatment.
The combination of FLX and MET led also to increased
IGF2 expression and enhanced LTP, specifically in the dorsal
hippocampus, at the end of treatment.
Previous findings by us [5, 10] indicate that FLX alone
administered in a chronic stress condition has limited
beneficial effects or leads to a worsening of depression-like
behavior. This is in line with previous studies [31–34].
However, other studies found that mice treated with SSRI
in a stressful environment show an improvement of the
depression-like profile [35, 36]. Here, we confirm that, com-
pared to VEH, FLX has limited beneficial effects when
administered in adverse conditions. However, the cotreat-
ment of MET and FLX counteracts the detrimental effects
induced by the exposure to stress following 1 week of treat-
ment. In particular, FLX and MET combination increases
the saccharin preference to the level that the mice had before
chronic stress compared to both VEH and FLX alone. Similar
results have been found for wanting-type anhedonia, mice












































Figure 3: LTP in the dorsal and ventral hippocampus is differentially affected by fluoxetine, metformin, or their combination. (a) LTP from
extracellular records in the dorsal and ventral hippocampi. The time course of fEPSP slope responses evoked at 0.05Hz and normalized as
detailed in Materials and Methods. Arrows indicate repeated spaced HFS (100Hz trains of 1 sec duration, 30minutes apart). Treatments
as indicated in the legend (in the dorsal hippocampus, VEH: n = 12/8, FLX: n = 10/9, MET: n = 12/9, and FLX-MET: n = 10/7 and in the
ventral hippocampus, VEH: n = 10/10, FLX: n = 8/8, MET: n = 9/8, and FLX-MET: n = 11/9). Note that in the dorsal hippocampus,
FLX-MET mice show an increased LTP compared to MET or VEH mice and that in VEH, LTP is higher in the ventral compared to
the dorsal hippocampus. Tukey’s t-test post hoc analysis, 20 minutes after the second HFS. ∗p < 0 05 FLX-MET vs VEH; ∧p < 0 05
FLX-MET vs MET. (b) PPR. Bar histogram indicates averaged PPR values for the dorsal hippocampus (VEH: n = 20/12, FLX: n = 20/12,
MET: n = 19/11, and FLX-MET: n = 21/12) and ventral hippocampus (VEH: n = 14/11, FLX: n = 16/11, MET: n = 21/12, and FLX-MET:
n = 16/10). Note that PPR is not affected by treatments and it is higher in the dorsal compared to the ventral hippocampus. Treatments
as indicated in the legend, £££p < 0 001, the main effect of the hippocampal region. Data are presented as mean + SEM.
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treated with the combined treatment showing a higher moti-
vation to obtain the reward compared to those receiving FLX
only. The results collected at four weeks show no difference
among the experimental groups, indicating that the com-
bined treatment has not long-lasting beneficial effects on
depression-like behavior and should be used for subacute
interventions. It is worth noting that, when administered in
standard condition, treatments did not produce different
effects, all experimental groups showing a recovery of the
anhedonic profile at both weeks 1 and 4 (Figure S2). These
results confirm that the MET-FLX combination is an
effective therapeutic approach when administered to
subjects living in stressful conditions and support our
hypothesis that FLX treatment outcome depends on the
quality of the environment [7].
To explore the molecular mechanisms associated to the
therapeutic action of the combined treatment, we analyzed
the expression of selected genes reportedly involved in
MDD and modulated by FLX and MET [37, 38]. In particu-
lar, we focused on IGF2 that is a key molecule in vulnerability
to stress and a potential molecular target able to trigger anti-
depressant action [39–41]. A decrease in IGF2 hippocampal
expression is significantly associated to depression-like
behavior induced through chronic restraint stress [40–42].
Accordingly, IGF2 overexpression was found to rescue the
neurobehavioral effects of stress exposure [40]. In addition,
recent evidence indicates that IGF2 administration enhances
adult neurogenesis in the hippocampal dentate gyrus [43],
considered a marker of recovery fromMDD [44, 45], indicat-
ing IGF2 as involved in switching from depressive-like to
healthy phenotype. IGF2 has been also reported to be a key
target of ketamine [39], a novel antidepressant drug, which
has a rapid but not long-lasting action [46], similarly to the
effect of the combined FLX-MET treatment reported here.
This suggests that IGF2 might be involved mainly in the
first-phase recovery from MDD. Here, we found that IGF2
is significantly increased by the combined treatment com-
pared to VEH and FLX alone, suggesting that this growth
factor might be involved in the antidepressant action of the
FLX-MET treatment. However, since IGF2 expression has
been associated to enhanced learning and memory [47], the
differences in wanting-type anhedonia, assessed through a
progressive ratio learning paradigm, could be ascribed also
to the differences in learning abilities associated to IGF2
levels. The differences in the IGF2 expression levels concern
mainly the dorsal hippocampus. Despite that the classic
view on anatomical segregation of the hippocampal func-
tion considers the dorsal part to be involved in learning
and memory while the ventral part in emotional and stress
responses [48, 49], an increasing number of studies are
challenging this dichotomy view [50, 51]. Indeed, novel evi-
dence indicates that the dorsal hippocampus is implicated
in MDD [52–54] and is an important target for antidepres-
sants [29, 30, 53–55]. For instance, though the ventral region
shows the highest expression levels of most markers of anti-
depressant action, such as the 5HT1A receptor in the dentate
gyrus [56], the dorsal region expresses at high levels specific
markers, including the 5-HT6 receptor, emerging as relevant
regulators of depression-like behavior as well [57, 58].
We also analyzed the expression levels of other metabolic
markers related to MDD such as IGF1, p11, BDNF, and
leptin, but these were not affected by treatments. Neverthe-
less, all of them showed a significantly different expression
in the two hippocampal regions. The adipose-derived hor-
mone leptin is well known for its function in controlling
energy homeostasis and has been recently involved in regu-
lating mood and emotion [59, 60]. Low levels of leptin are
associated to depression in humans, and preclinical models
as well as pharmacological studies indicate leptin as a poten-
tial antidepressant drug [61]. Here, we observe an higher
leptin expression in the ventral compared to the dorsal
hippocampus. Such specificity is in line with previous data
showing that leptin differently affectsmemory and food intake
when administered in the dorsal or the ventral hippocampus
[62]. Similar to leptin, the expression of p11 (also known as
S100A10), involved in the regulation of depression-like
behavior and response to antidepressants [63–65], was not
modified by treatments but its expression levels were higher
in the ventral compared to the dorsal hippocampus.
BDNF is a neurotrophic factor particularly abundant in
hippocampal neurons [66] that has been indicated as a key
player in the pathophysiology of MDD. Indeed, according
to the “neurotrophic hypothesis of depression,” the psycho-
pathology is associated with the reduction of brain BDNF
levels and antidepressant treatments alleviate depressive
symptoms increasing its levels [6, 67]. BDNF is reported to
be expressed at higher levels in the dorsal compared to the
ventral hippocampus [68]. We here confirm this finding. In
addition, we replicate data from our and other research
groups showing that FLX treatment does not increase the
levels of this neurotrophin in a stressful environment [4].
In line with previous data, BDNF levels were not affected also
by MET [69]. Akin to IGF1, BDNF levels were higher in the
dorsal compared to the ventral hippocampus.
Similar to gene expression, physiological properties differ
along the longitudinal axis of the hippocampus. For instance,
in the CA1 region [70–72], the LTP magnitude is smaller in
the ventral than in the dorsal hippocampus [73–75] and is
differentially modulated by stress in the two regions [76–
81], being reduced or not affected in the dorsal but increased
in the ventral hippocampus following both acute stress [82,
83] and chronic stress [27]. In line with these findings, we
show here that the LTP magnitude was smaller in dorsal
compared to ventral hippocampus. This might be due to
the different distribution and effects exerted by the cortico-
steroid receptors, mineralocorticoids (MRs) and glucocorti-
coids (GRs), on LTP after exposure to stress. In particular,
it has been reported that MRs, more expressed in the ventral
part [84], facilitate LTP [85, 86], while GRs, more abundant
in the dorsal part of the hippocampus [84], impair LTP [87].
Interestingly, the treatments differentially affected LTP in
the two hippocampal regions. In particular, the FLX-MET
cotreatment produced a significant increase in LTP ampli-
tude in the dorsal hippocampus, which parallels the signifi-
cant IGF2 expression increase observed in this region.
Given the role of IGF2 in modulating biological processes
involved in neuronal plasticity [88], such as promoting
dendritic spine formation [89] and enhancing pERK1/2 and
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GluR1 [47], the IGF2 increase might be involved in the
plasticity enhancement that we observed. By contrast, no
significant difference in LTP was found in the ventral part,
suggesting that FLX and MET, alone or in combination, do
not regulate plasticity in this area. This evidence suggests that
the FLX and MET combination affects the electrophysiolog-
ical activity specifically in the dorsal hippocampus which
has been reported as a potential target for antidepressant
treatments [29, 30, 53–55]. Such LTP amplitude enhance-
ment, in addition to the increased IGF2 expression, in a brain
region reportedly involved in learning processes further
supports that these changes might contribute to the differ-
ences in the progressive ratio paradigm used to assess
wanting-type anhedonia.
The major limitations of the present study include the
lack of the analysis of the molecular and cellular endpoints
after 1 week of treatment in order to better investigate the
association between behavioral changes and modifications
in neurophysiological substrates. In addition, a pharmacoki-
netic analysis of the possible interaction between metformin
and fluoxetine would have better illustrated whether the
coadministration affects their bioavailability. Finally, given
that MDD affects mostly female with a female :male ratio of
approximately 2 : 1, the assessment of the effect of the treat-
ments not only in males but also in female individuals will
be extremely relevant.
5. Conclusions
In conclusion, previous works by us and others have found
that FLX administration has beneficial effects in an enriched
environment but has no effects or even leads to detrimental
outcome when administered in a stressful environment
[4, 5, 90]. Here, we show that the combined FLX and
MET treatment is more effective than FLX and VEH alone
in a short term when administered in individuals exposed
to a stressful condition. Therefore, this polypharmacological
strategy appears effective to counteract the potential limited
efficacy of FLX in individuals living in adverse conditions.
This might be highly relevant in the clinic because, with very
few exceptions, people cannot rapidly and effectively change
their life circumstance and adverse conditions are very com-
mon in depressed patients.
Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request.
Disclosure
The Italian Ministry of Health and the ERANET agency had
no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; prepa-
ration, review, or approval of the manuscript; and decision to
submit the manuscript for publication. An earlier version of
the present study has been presented as conference abstract
at the 31st ECNP Congress—Barcelona 2018.
Conflicts of Interest
The authors declare that there is no conflict of interest
regarding the publication of this paper.
Authors’ Contributions
Silvia Poggini and Maria Teresa Golia equally contributed
as first authors; Laura Maggi and Igor Branchi equally
contributed as last authors.
Acknowledgments
Nadia Francia and Stella Falsini (Istituto Superiore di Sanità)
provided editorial support. The research was supported by
the grant from the Italian Ministry of Health Ricerca Fina-
lizzata (RF-2011-02349921) and ERANET Neuron 2017
MicroSynDep (both to IB).
Supplementary Materials
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Mice were exposed to stress for six weeks. The first two weeks
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four weeks of stress, the subjects were treated with fluoxetine,
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design and effects of fluoxetine, metformin, or their combi-
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condition to induce a depression-like phenotype. Afterwards,
they were treated for four weeks in the standard condition.
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